4.6 Editorial Material

What is the optimal use of bevacizumab in glioblastoma?

期刊

NATURE REVIEWS NEUROLOGY
卷 11, 期 8, 页码 429-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nrneurol.2015.127

关键词

-

向作者/读者索取更多资源

Bevacizumab is approved for use in recurrent glioblastoma, but whether it benefits patients with newly diagnosed glioblastoma remains unclear. Two new studies further question the use of the bevacizumab in this context, but leave much to be clarified about its optimal clinical application.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据